Patient advocacy groups continue to mobilise and play an increasingly important role in delivering advice and support helping to get treatments to those most in need by Influencing many elements of drug development and patient access processes. This is very much the case in rare disease where groups give critical support to patients and those close to them through influential programmes delivered with passion and dogged persistence.
Biopharma recognises the importance of positive engagement and partnership with patient groups. Gaining a far greater understanding of the patient journey helps to translate innovations into actual benefits for patients and caregivers in improved clinical outcomes and patient experience.
A question remains around how, and which part of a biopharma organisation should be involved in building patient group relationships. Many organisations invest in patient advocacy leads to support engagement, but they are often brought in to support dialogue as a new treatment is becoming available. As patient groups are rightly getting involved in activities much earlier in the drug development process who should lead engagement at this stage and support over the longer term?
This was a question that was posed at workshops during the recent Medical Affairs Professionals (MAPS) meeting in Europe. MAPS is an organisation that supports the sharing of best practice amongst leaders in this key function of pharmaceutical companies. So, who are medical affairs and what is their role?
Read the full article here: https://bit.ly/37IYg5